aceAstraZeneca strikes $40 million AI drug discovery deal with insitro
AstraZeneca has entered a collaboration with insitro to explore new treatment options for challenging liver and heart diseases. The partnership involves a $40 million upfront payment and potential milestones totaling approximately $1.46 billion. Insitro will utilize its AI platform to identify biological drivers for metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Following this, AstraZeneca will manage clinical trials and further development. This collaboration signifies insitro's growing…
AstraZeneca is paying insitro $40 million upfront, with possible milestones of about $1.46 billion, to use an AI platform to find biological drivers of liver and heart diseases.
The article describes only a planned collaboration and potential milestone payments; it does not report any discovered targets, clinical trial results, or patient outcomes.
Evidence
- JournalismThe Economic Times2026-10-15
How should this claim be treated?
Truvace Impact Record TRV-2026-1569, v1: “AstraZeneca strikes $40 million AI drug discovery deal with insitro.” Truvace, 2026-10-16. /record/TRV-2026-1569 (accessed at citation time). sha256 7ac7b406ee846e77…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-1569 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.